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increases skeletal muscle mass, but whether IGF-I increases type IIb 
myosin heavy chain (MyHC) transcriptional activity is not known. 
C2C12 myotubes were cultured with or without IGF-I to determine 
whether IGF-I increases type IIb MyHC promoter activity, and if so, 
what region of the promoter might IGF-I signaling regulate. At 
differentiation days 3 and 4, IGF-I increased type IIb MyHC mRNA 
and mouse 3.0-kb type IIb MyHC promoter activity. Deletion 
construct studies identified a potential IGF-I-responsive region 
between 
1.25 and 1.2 kb of the type IIb MyHC promoter, which contained an 
exact 6-bp T-cell factor/lymphoid enhancer factor (Tcf/Lef) binding 
site at position -1206 to -1201. Site-specific mutation of the putative 
Tcf/Lef binding site reduced IGF-I-induced 1.3-kb type IIb MyHC 
promoter activity. To identify potential IGF-I signaling molecules, the 
phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY- 
294002 were both found to markedly attenuate IGF-I activation of the 
1.3-kb type IIb MyHC promoter. Downstream signaling of IGF-I can 
phosphorylate and inactivate GSK-313, thereby enhancing 13-catenin 
protein. The GSK-313 inhibitor, LiCl, dramatically enhanced IGF-I 
induction of the 1.3-kb type IIb MyHC promoter, and constitutively 
active GSK-313 attenuated IGF-I-induced 1.3-kb type IIb MyHC 
promoter activity. Finally, IGF-I increased nuclear 13-catenin protein, 
and small interfering RNA knockdown of 13-catenin attenuated IGF- 
I-induced 1.3-kb type IIb MyHC promoter activity and type IIb 
MyHC mRNA. In summary, IGF-I stimulation of C2C12 myotubes 
increases mouse type IIb MyHC promoter activity, likely through 
signaling of PI3K, GSK-313, 13-catenin, and a Tcf/Lef binding site at 
-1,206 to -1,201 bp in the promoter. 
insulin-like growth factor I; C2C12 myocytes; 13-catenin 
EXOGENOUS IGF-I DELIVERED either through osmotic pumps (1) or 
genetic overexpression (20) results in greater skeletal muscle 
mass in rodents. A similar response has been noted on appli- 
cation of IGF-I to cultured myotubes, where larger myotube 
diameters and higher protein contents have been reported (22, 
33). To increase muscle mass, IGF-I would have to increase 
myosin heavy chain (MyHC) expression, because it is a major 
contractile protein in skeletal muscle. MyHC has multiple 
isoforms in limb skeletal muscle (MyHC I, IIa, IIx/d, and IIb), 
each with its own gene (24). Barton-Davis et al. (3) demon- 
strated that overexpression of IGF-I for 9 mo in extensor 
digitorum longus (EDL) muscles (primarily composed of type 
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IIb fibers) prevented muscle atrophy and the loss of type IIb 
fibers in old mice. In transgenic mice that overexpress IGF-I in 
skeletal muscle, the cross-sectional diameter of type IIb fibers 
was increased (20). In addition, Flint et al. (10) demonstrated 
that IGF-I overexpression in denervated muscle prevents the 
loss of type IIb MyHC protein. We therefore chose to study 
whether IGF-I signaling increases type IIb MyHC promoter 
activity in mouse skeletal muscle. Our notion is that an IGF-I 
downstream target, such as type IIb MyHC, could serve as a 
source to identify a potential regulatory site for IGF-I interac- 
tions with other genes. 
Under steady-state conditions, most agree that MyHC genes 
are regulated at the transcriptional/pretranslational level (2). 
Nuclear run-on assays indicate that the type IIb MyHC gene is 
transcriptionally activated as myoblasts fuse and mature to 
myotubes in tissue culture (7) and during whole skeletal 
muscle development (6). These observations have been con- 
firmed and extended by others. Swoap (28) and Wheeler et al. 
(34) determined that the type IIb MyHC promoter has �35 
times greater in vivo transcriptional activity in the rat tibialis 
anterior muscle [26 – 46% IIb fibers (9)] than in the slow-twitch 
soleus [0% IIb fibers (9)]. Furthermore, changes in contractile 
activity, e.g., muscle training or hindlimb unloading, can alter 
MyHC phenotype, and these changes at the protein level are 
preceded by changes at the mRNA level (4, 13, 15). Nonethe- 
less, how IGF-I modulates type IIb MyHC and many other 
skeletal muscle genes remains unknown. To our knowledge, 
there are no data at the level of the type IIb MyHC promoter 
that support a role for IGF-I increasing type IIb MyHC mRNA. 
Therefore, the purpose of the current study was to investigate 
whether IGF-I increases type IIb MyHC promoter activity and 
potential signaling mechanism(s) associated with its increase. 
METHODS 
Cell culture. All cell culture experiments were performed with 
C2C12 myoblasts (American Type Culture Collection CRL-1722) 
under standard conditions (37°C and 10% CO2) and maintained at a 
subconfluent density in growth medium (GM). GM consisted of 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco), 20% (vol/vol) 
fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 
40 µg/ml gentamicin. Transient transfections were performed using 
0.078 pmol of plasmid DNA and Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s recommendations in antibiotic-free 
GM for 6 h. Differentiation was induced 18 h after transfection by 
replacing the GM with differentiation media [DM; DMEM, 2% 
(vol/vol) horse serum] or DM + IGF-I (250 ng/ml; PeproTech). DM 
and DM + IGF-I were replaced every 24 h. Dimethyl sulfoxide 
(vehicle), lithium chloride [10 mM (21)], wortmannin [100 nM (8)], 
LY-294002 [10 µM (32)], and rapamycin [1 µg/ml (25)] were 
purchased from Sigma Chemicals. The constitutively active glycogen 
synthase kinase-313 plasmid, pGSK-3A9 (caGSK-313), was a gift from 
James R. Woodgett (University of Toronto, Toronto, ON, Canada) 
(26). The 13-catenin antibody was purchased from Cell Signaling (no. 
9581). 
Generation of promoter reporter, 5'-deletion constructs, and site- 
directed mutagenesis. The 2,567-base pair (bp) mouse type IIb MyHC 
promoter sequence published by Takeda et al. (29), accession number 
M92099, was used to generate the �3,000-bp (3.0-kb) type IIb MyHC 
promoter and subsequent constructs as follows. The published se- 
quence was input into the University of California Santa Cruz Ge- 
nome Bioinformatics database (http://genome.ucsc.edu) (17), and 414 
additional bases at the 5'-end were retrieved. Thus, 2,981 bp of the 
5'-flanking region (-2,968 bp - +13 bp relative to the transcription 
start site) of the mouse type IIb MyHC gene were polymerase chain 
reaction (PCR) amplified from purified bacterial artificial chromo- 
some DNA. Briefly, searching the National Center for Biotechnology 
Information (NCBI) nucleotide data base revealed that clone RP23- 
294E23 (accession no. AL596129.27) contains the region of chromo- 
some 11 with the MyHC IIb gene (myh4, GeneID: 17884) and its 
5'-flanking region (M92099). The clone and the promoter were aligned 
via the NCBI Basic Local Alignment Search Tool (http://blast.ncbi.nlm. 
nih.gov) for confi The bacterial artifi chromosome containing 
clone RP23-294E23 was purchased from Invitrogen. PCR-based methods 
using AccuPrime Pfx DNA polymerase (Invitrogen) and primers with 
engineered Mlu I (5'-primers) and Sma I (3'-primers) restriction 
endonuclease sites for subsequent ligation were used to amplify the 
3,000 bp type IIb MyHC promoter segment. Following restriction 
endonuclease digestion, the promoter clone was ligated into the 
multiple cloning site of the pGL3 Basic (Promega) reporter vector 
driving firefly luciferase expression, termed the 3.0-kb type IIb MyHC 
promoter reporter. Restriction enzyme digest and automated 
bidirectional sequencing (University of Missouri-Columbia DNA 
Core Facility) were used to confirm insert size, PCR fidelity, and 
insert orientation of the entire 2,981 bp. Nineteen 5'-deletion 
constructs were made using the 3.0-kb type IIb MyHC promoter 
construct as the template using primers with engineered Mlu I and 
Sma I restriction endonuclease sites and annealed to the reporter 
vector. Each 5'- deletion construct has a numerical designation 
referring to the 5'- promoter sequence most relative to the 
transcription start site, and the 3'-end of all constructs ends at +13 
relative to the transcription start site. 
Site-specific mutations on the 1.3-kb type IIb MyHC promoter 
were accomplished using the Quick Change II site-directed 
mutagen- 
esis kit (Stratagene). Complementary DNA oligos were created 
changing three bases (-1206, -1204, -1202) from the target se- 
quence in the center of the oligos (underlined in each sequence); 
forward primer sequence: GAACACTTTTCTTTCCGGTTCTTAGC- 
CTAACACTTGGGG; reverse primer sequence: CCCCAAGTGT- 
TAGGCTAAGAACCGGAAAGAAAAGTGTTC. Mutated plasmids 
were amplified by PCR, followed by the digestion of template 1.3-kb 
type IIb MyHC plasmid with Dpn I. Plasmids were transformed and 
grown up in One Shot Top10 competent cells (Invitrogen) and 
purified with the Qiafilter Plasmid Midi Kit (Qiagen). 
Small interfering RNA transfections. To optimize transfection con- 
ditions, C2C12 myoblasts were cotransfected with the wild-type 1.3-kb 
type IIb MyHC promoter (same concentration as previous experi- 
ments; 0.078 pmol) and increasing concentrations of either three 
different small interfering RNA (siRNA) constructs against mouse 
13-catenin (s63417; no. 1, s63418; no. 2, and s63419; no. 3), non-
targeting, negative control siRNA (NT siRNA; 4390843), or 
GAPDH- positive control siRNA (4390849), all from Applied 
Biosystems (AB). Preliminary experiments on 13-catenin siRNA 
constructs re- vealed that siRNA construct no. 3 (s63419) was the 
most effective of the three. Optimization experiments on 13-catenin 
siRNA construct no. 3 revealed �80% knockdown of 13-catenin 
mRNA with transfection of 3–9 nM (Fig. 7B); therefore 3 nM 13-
catenin siRNA construct no. 3 was used for the remaining siRNA 
experiments. For type IIb MyHC promoter activity and mRNA 
experiments with 13-catenin siRNA, C2C12 myoblasts were 
cotransfected with either the wild-type or mutated 1.3-kb type IIb 
MyHC promoter and/or either 3 nM 13-catenin siRNA or 25 nM NT 
siRNA using Lipofectamine 2000. At 24 h posttransfection, cells 
were washed with PBS and changed to DM or DM + IGF-I (250 
ng/ml). Cells were harvested after 3 days of differentiation and 
analyzed for type IIb MyHC promoter luciferase activity or type 
IIb MyHC mRNA. 
Real-time PCR. Total cellular RNA was isolated from C2C12 
myotubes at specified time points (QIAshredder and RNeasy Micro; 
Qiagen) and reverse transcribed (Superscript III First-Strand 
Synthesis System; Invitrogen) using random hexamers. Each 
reaction, per- formed in duplicate, contained 25 ng cDNA, 250 nM 
MGB probe, 900 nM primers, and Taqman Universal PCR Master 
Mix (AB) in a 25-µl volume. An AB Prism 7000 sequence detection 
system was used for all real-time PCR reactions. Type IIb MyHC 
primers and probe were designed using Primer Express (AB); 
forward primer sequence: GAGAGGTGACAGGAGAAATCACAA; 
reverse primer sequence: 
TGCAGAATTTATTTCCGTGATATACAC; probe sequence: TGT- 
 
 
 
 
 
 
 
 
Fig. 1. C2C12 differentiation time course. 
Representative photomicrographs of C2C12 
myocytes at the time differentiation was ini- 
tiated (day 0) and after 1– 4 days of differen- 
tiation in differentiation media (DM; control) 
or DM with 250 ng/ml of insulin-like growth 
factor I (IGF-I). Bar in top right corner = 
200 µm. 
 
 
 
 
 
GACGTTCTTTGTCACTGT. Relative changes in type IIb MyHC 
mRNA levels were determined using the LiLiCt method (where Ct is 
threshold cycle; AB User Bulletin no. 2) and normalized to 18S rRNA 
(18S was not different over time or with IGF treatment). TaqMan 
Ribosomal RNA control reagents (AB) were used to determine 18S 
levels. 13-Catenin mRNA levels were determined using the AB 
TaqMan Gene Expression Assay mix (AB; Mm00483033_m1) and 
normalized to GAPDH mRNA (AB, Endogenous Control mix; 
4352339E) with Universal PCR Master Mix. 
Reporter gene analysis. At the specified time points, cells were 
harvested with Passive Lysis Buffer (Promega) and stored at -80°C 
until analysis. Firefly luciferase activity was determined using Lucif- 
erase Assay Reagent II according to the manufacturer’s instructions 
(Promega) and measured using a Veritas Microplate Luminometer 
(Turner BioSystems). Firefly luciferase activity was normalized to 
control (non-IGF-I) 3.0-kb or 1.3-kb type IIb MyHC promoter activ- 
ity. 
Nuclear isolation and Western blot. Myotubes were harvested after 
3 days of differentiation with or without 250 ng/ml of IGF-I, and 
nuclei were isolated using the NE-PER Kit (Pierce; Rockford, IL) 
with protease and phosphatase inhibitors (Sigma) per the manufactur- 
er’s instructions. Enriched nuclear extract protein concentrations were 
determined using the BCA protein assay kit (Pierce). Equal amounts 
of enriched nuclear extract protein were separated by SDS-PAGE and 
subsequently transferred to nitrocellulose membranes. Membranes 
were stained with Ponceau S (Sigma), and the image was quantified to 
verify equal loading [P = 0.576; data not shown (19)]. 13-Catenin 
protein was analyzed by Western blot and detected with a primary 
antibody from Cell Signaling Technology (no. 9562; Beverly, MA) 
and horseradish peroxidase-conjugated secondary antibody and Su- 
perSignal West Dura chemiluminescence reagent from Pierce. Immu- 
noblots were developed and analyzed using the Kodak 4000R Mo- 
lecular Imaging System (Rochester, NY). 
Statistical analysis. Type IIb MyHC and 13-catenin mRNA and all 
promoter data were analyzed by analysis of variance, and where 
significant differences existed, a Newman-Keuls test was used post 
hoc. Enriched nuclear extract 13-catenin protein was analyzed by 
Student’s t-test. Significance was established at P < 0.05. Data are 
reported as means ± SE. 
 
RESULTS AND DISCUSSION 
 
Barton-Davis et al. (3) previously reported that overexpres- 
sion of IGF-I completely prevents the age-related loss of type 
IIb muscle fibers in old mouse EDL muscle. In addition, IGF-I 
has been shown to increase type IIb MyHC protein in dener- 
vated skeletal muscle (3, 10). However, mechanisms that might 
regulate type IIb MyHC expression in response to IGF-I are 
largely unknown. Since type IIb MyHC expression is transcrip- 
tionally regulated in response to thyroid hormones and me- 
chanical stimuli (2), it seemed logical to hypothesize that IGF-I 
might increase type IIb MyHC promoter activity. Therefore, 
the purpose of this study was to investigate whether IGF-I 
increases type IIb MyHC promoter activity using reporter gene 
assays and, if so, to identify a regulatory element and potential 
upstream signaling to this element. Using C2C12  muscle cells, 
we demonstrate, for the first time, that IGF-I increases type IIb 
MyHC mRNA levels and activity of the type IIb MyHC 
promoter. Furthermore, these novel findings suggest that IGF- 
I-induced promoter activity of type IIb MyHC involves GSK- 
313, 13-catenin, and a putative Tcf/Lef binding site in the 
promoter region of the type IIb MyHC gene. 
IGF-I induces type IIb MyHC promoter activity. To inves- 
tigate whether IGF-I increases type IIb MyHC mRNA, we 
differentiated C2C12  muscle cells with or without IGF-I for 4 
days (Fig. 1). Type IIb MyHC mRNA was not detectable in 
undifferentiated myocytes (data not shown), nor was it detect- 
able after 1 day of differentiation under control or IGF-I 
conditions (data not shown). In the absence of IGF-I, type IIb 
MyHC mRNA levels increased 2- and 5-fold at differentiation 
days 3 and 4, respectively, as compared with day 2 (Fig. 2A). 
These data are in accordance with a previous study reporting 
increased levels of type IIb MyHC mRNA during differentia- 
tion without added IGF-I (30). However, when IGF-I was 
added to the differentiation media, type IIb MyHC mRNA 
levels increased to a greater degree than without IGF-I (12- and 
7-fold at days 3 and 4 of differentiation, respectively) (Fig. 
2A). Based on our finding that IGF increases type IIb MyHC 
mRNA and on the fact that mRNA levels are determined by the 
rates of transcription and/or mRNA stabilization and MyHC 
gene transcription is a primary regulatory point for MyHC 
expression (see Ref. 2 for reference), promoter analysis studies 
were pursued. 
To examine whether the IGF-I-induced increases in type IIb 
MyHC mRNA were due to increased activity of the type IIb 
MyHC promoter, we constructed a promoter reporter contain- 
 
 
 
 
 
 
 
 
 
Fig. 2. Time course of type IIb myosin heavy chain (MyHC) mRNA levels (A) 
and type IIb MyHC promoter activity (B) in differentiating C2C12 myocytes. 
C2C12 myocytes were harvested after 1– 4 days of differentiation in DM 
(control) or DM with 250 ng/ml IGF-I (IGF-I). Type IIb MyHC mRNA was 
not detectable at the time differentiation was initiated (day 0) nor after 1 day 
of differentiation under control or IGF-I conditions (data not shown). Type IIb 
MyHC mRNA was detectable after 2 days under IGF-I conditions, but because 
of the scale of the graph the data are not visible. Data are reported as the 
average ± SE of n = 4 wells/group. *P < 0.05 from time-matched control, 
#P < 0.05 from earliest day control, $P < 0.05 from earliest day IGF-I. 
 
 
ing �3,000 bp (3.0-kb) of the mouse type IIb MyHC promoter 
region. C2C12 muscle cells transfected with the 3.0-kb type IIb 
MyHC promoter reporter were differentiated with or without 
IGF-I for 3 days, and luciferase promoter activity assays were 
performed. Type IIb MyHC promoter activity was detectable, 
albeit low, in the presence and absence of IGF-I after 1 day of 
differentiation. However, by days 2 and 3 of differentiation, 
IGF-I  increased  type  IIb  MyHC  promoter  activity  2-  and 
�3-fold, respectively, compared with no added IGF-I (Fig. 
2B). Together, these data show that IGF-I enhances type IIb 
MyHC promoter activity in differentiating C2C12  myocytes. 
Deletion analysis reveals an IGF-I responsive region be- 
tween -1,250 and -1,200 bp on the type IIb MyHC promoter. 
To determine the region(s) of IGF-I-induced transcriptional 
activity in the type IIb MyHC promoter, 5'-deletion constructs 
were generated from the 3.0-kb type IIb MyHC promoter 
reporter. Luciferase promoter activity assays revealed three 
potential IGF-I-responsive regions in the type IIb MyHC 
promoter:  -1,300  to  -1,200;  -1,100  to  -1,000;  and  -500 
to 
-400 bp (Fig. 3A). Of the three potential IGF-I-responsive 
regions  in  the  type  IIb  MyHC  promoter,  the  -1,300-  to 
-1,200-bp deletion produced the largest decrement in IGF-I 
activation, and therefore the -1,300- to -1,200-bp region was 
pursued. When an additional 50-bp deletion construct was 
generated between -1,300 and -1,200 bp (1.25-kb), a 
significant decrease in IGF-I-induced promoter activity was 
detected between the 1.25-kb to 1.2-kb constructs, but not 
between 1.3-kb and 1.25-kb (Fig. 3B), suggesting a 
potential IGF-I- responsive region between -1,250 and -
1,200 bp in the type IIb MyHC promoter. 
IGF-I-PI3K/Akt-GSK-3[3 signaling to the type IIb MyHC 
promoter. IGF-I signaling activates the phosphatidylinositol 
3-kinase (PI3K)/Akt pathway in skeletal muscle hypertrophy 
(for review see Ref. 12). Downstream signaling from the IGF-I 
receptor and PI3K involves Akt-directed phosphorylation and 
inactivation of glycogen synthase kinase-313 (GSK-313) in 
skeletal muscle cells (8, 32, 33). 
To gain insight into potential IGF-I signaling mechanism(s) 
to the -1,300 to -1,200 bp region of the type IIb MyHC 
promoter, a pharmacological approach was first undertaken. 
C2C12 muscle cells were differentiated with or without IGF-I 
for 3 days; the pharmacological inhibitors for molecules in- 
volved in the PI3K signaling cascade were added during the 
final 24 h. Inhibiting PI3K with wortmannin completely 
abolished 1.3-kb type IIb MyHC promoter activity (Fig. 4A) 
and type IIb MyHC mRNA (Fig. 4B) in response to IGF-I. 
The PI3K inhibitor, LY-294002, and the inhibitor of 
mammalian target of rapamycin (mTOR; a downstream target 
of PI3K/Akt signaling), rapamycin, both significantly 
attenuated type IIb MyHC promoter activity (Fig. 4A) and 
type IIb MyHC mRNA levels (Fig. 4B) in response to IGF-I, 
implying that multiple pathways may be involved in 
signaling to the type IIb MyHC promoter. A possible 
limitation to our pharmacological approach is that 
wortmannin, LY-294002, and rapamycin can specifically 
inhibit transcription and/or translation of the lucif- erase 
reporter gene, or have nonspecific effects on general 
transcription and/or translation. Additionally, it should be 
emphasized that inhibitors were present in the differentiation 
media for only the last 24 h; thus, normal expression of 
trans-activating factors of IGF-I signaling molecules were not 
impacted by the inhibitors during the initial 48 h of 
differentiation. These data (Fig. 4, A and B) suggest that the 
significant increases in type IIb MyHC mRNA (Fig. 2A) 
and promoter activity by IGF-I (Fig. 2B) that occur between 
48 and 72 hrs of differentiation likely require IGF-I activation 
of PI3K/Akt signaling. 
Fig. 3. IGF-I responsiveness in type IIb 
MyHC promoter activity is lost with 5'-de- 
letions. C2C12 myocytes were harvested after 
3 days of differentiation in DM (control) or 
DM with 250 ng/ml IGF-I (IGF-I), and type 
IIb MyHC promoter activity was assessed. 
A: successive 5'-deletions were made to the 
3-kb type IIb MyHC promoter. Values are 
expressed as a percentage of control 3-kb 
type  IIb  MyHC  promoter  activity  and  are 
reported as the average ± SE of n = 4 
wells/group. *P < 0.05 from control within 
same promoter length, $P < 0.05 from IGF-I 
3-kb activity. B: an additional 50-bp 5'-dele- 
tion between 1.3 kb and 1.2 kb revealed a 
potential IGF-I-responsive region in the type 
IIb MyHC promoter. Values are expressed as 
a percentage of control 3-kb type IIb MyHC 
promoter activity and are reported as the 
average ± SE of n = 4 wells/group. *P < 
0.05 from control within same promoter 
length, $P < 0.05 from IGF-I 1.3-kb and 
IGF-I 1.25-kb activity. 
mouse type IIb MyHC promoter. 13-Catenin, a transcriptional 
coactivator, binds to an NH2-terminal domain of Tcf/Lef fa- 
cilitating the assembly of multimeric complexes containing 
transcriptional coactivators, such as CBP/p300, BCL9/LGS 
and Pygo, which can activate transcription of target genes. 
Tcf/Lef proteins bind to a conserved DNA sequence, 
classically known as the Wnt-response element (WRE: C/T-
C-T-T- T-G-A/T-A/T) or as referred to here as the Tcf/Lef 
binding site (14). When canonical Wnt signaling is absent, 
GSK-313 phosphorylates 13-catenin, targeting it for 
ubiquitination and degradation by the proteasome, thereby 
disrupting the formation of these transcriptional complexes 
(see Refs. 11 and 35 for references). Previously, we reported 
that IGF-I phosphorylates and inactivates GSK-313 (33). 
Taken together, these data sug- gest a possible link between 
IGF-I/GSK-313 signaling, 13-catenin, and the Tcf/Lef 
binding element within this region of the type IIb MyHC 
promoter. 
To verify the putative Tcf/Lef binding site’s IGF-I 
responsiveness, we next performed site-directed mutagenesis 
on the 
-1,206 to -1,201 bp region of the 1.3-kb type IIb MyHC 
Fig. 4. Chemical inhibition of the 1.3-kb type IIb MyHC promoter and type IIb 
MyHC mRNA levels. C2C12 myocytes were harvested after 3 days of differ- 
entiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I). Vehicle 
(DMSO) or the inhibitors wortmannin (WM, 100 nM), LY-294002 (LY, 10 
µM), and rapamycin (Rap, 1 µg/ml) were added during the final 24 h of 3 days 
of differentiation. A: 1.3-kb type IIb MyHC promoter activity. Values are 
expressed as a percentage of control vehicle. B: type IIb MyHC mRNA levels. 
Values are expressed as a percentage of control vehicle and are reported as the 
average ± SE of n = 4 wells/group. *P < 0.05 from control within same 
treatment, #P < 0.05 from control vehicle, $P < 0.05 from IGF-I vehicle. 
Genetic (22) or chemical (33) inhibition of GSK-313 has 
been demonstrated to induce significant myotube hypertrophy. 
Thus, we sought to determine whether modulating GSK-313 
activity by chemical inhibition or genetic manipulation would 
alter type IIb MyHC promoter activity. We hypothesized that 
lithium chloride (LiCl), a noncompetitive inhibitor of GSK-313, 
would enhance IGF-I-induced activation of the 1.3-kb type IIb 
MyHC promoter. Indeed, addition of LiCl significantly in- 
creased both 1.3-kb type IIb MyHC promoter activity (Fig. 5A) 
and the levels of type IIb MyHC mRNA (Fig. 5B). Further- 
more, when IGF-I and LiCl treatments were combined, the 
effects on 1.3-kb type IIb MyHC promoter activity were 
additive, reminiscent of the additive effects of GSK-313 inhi- 
bition observed with the insulin-induced hypertrophic response 
in C2.7 myogenic cells reported by Rochat et al. (21). 
Promoter analysis reveals a putative Tcf/Lef binding ele- 
ment and [3-catenin as a potential link between IGF-I/GSK-3[3 
signaling and type IIb MyHC promoter activity. To further 
investigate the IGF-I-responsive region in the type IIb MyHC 
promoter at -1,300 to -1,200 bp, MatInspector (http://www. 
genomatix.de/) (5) was utilized to search this region for possible 
transcription factor binding sites. The search revealed an exact 
6-bp T-cell factor/lymphoid enhancer factor (Tcf/Lef) DNA 
binding  site  located  between  -1,206  and  -1,201  bp  of  the 
Fig. 5. Lithium chloride (LiCl) modulation of the 1.3-kb type IIb MyHC 
promoter and type IIb MyHC mRNA levels. C2C12 myocytes were harvested 
after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I 
(IGF-I). DMSO (vehicle) or LiCl (10 mM) was added during the final 24 h of 
3 days of differentiation. A: 1.3-kb type IIb MyHC promoter activity. Values 
are expressed as a percentage of control vehicle. B: type IIb MyHC mRNA 
levels. Values are expressed as a percentage of control vehicle and are reported 
as the average ± SE of n = 4 wells/group. *P < 0.05 from control within same 
treatment, #P < 0.05 from control vehicle, $P < 0.05 from IGF-I vehicle. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
promoter (Fig. 6A). Site-directed mutagenesis of three bases 
between -1206 and -1201 resulted in a 31% decrease in IGF-
I-induced type IIb MyHC promoter activity (Fig. 6B). 
These data suggest that a Tcf/Lef binding site at -1206 to 
-1201 on the type IIb MyHC promoter is functional and, for 
the first time, we demonstrate an IGF-I-responsive region on 
the type IIb MyHC promoter. 
Next, to further examine the potential linkage of GSK-313 to 
the type IIb MyHC promoter, we employed a genetic approach 
to modulate GSK-313 activity in the opposite direction as LiCl. 
We tested whether a constitutively active GSK-313 (caGSK-313) 
would attenuate the increase in type IIb MyHC promoter 
activity in response to IGF-I. Overexpression of caGSK-313, in 
the absence of IGF-I, did not affect 1.3-kb type IIb MyHC 
promoter  activity.  However,  in  the  presence  of  IGF-I,  the 
IGF-I-induced increase in type IIb MyHC promoter activity 
was significantly attenuated by 41% with caGSK-313 (Fig. 6C), 
suggesting that IGF-I-induced inactivation of GSK-313 may 
play an important role in transcriptional activation of type IIb 
MyHC. 
To this point, we have reported that both site-directed 
mutagenesis of the -1206 to -1201 Tcf/Lef binding site and 
overexpression of caGSK-313 (Fig. 6, B and C, respectively) 
each attenuate, but do not completely abolish IGF-I-induced 
increases in 1.3-kb type IIb MyHC promoter activity. These 
data suggest that mutation of the Tcf/Lef binding site and 
overexpression of caGSK-313 have similar effects on inhibiting 
IGF-I signaling to the type IIb MyHC promoter. Therefore, we 
were surprised with the finding that combining both the mutant 
1.3-kb type IIb MyHC promoter and caGSK-313 together 
induced further attenuation of 1.3-kb type IIb MyHC 
promoter activity in response to IGF-I (Fig. 6C). 
Cross-species nucleotide sequence comparisons showed 
100% conservation of the core nucleotide sequence for Tcf/Lef 
binding sites in the mouse, rat, human, and chimp type IIb 
MyHC promoters, despite differences in location across 
species (Fig. 6D). The 5'- and 3'-flanking regions, however, 
showed less than perfect sequence homology across species. 
Divergence in core element location and 5'- and 3'-flanking 
region sequence is thought to allow for different binding 
factors to interact within the transcriptional complex and is 
likely to confer developmental-, tissue-, or perturbation-
specific responsiveness (18). For example, the proximal 
MCAT binding site on the 13-MyHC promoter is highly 
conserved between human and rat; however, sequence 
divergence of the 5'-flanking  region  of  this  MCAT  
element  exerts  profound 
 
 
 
Fig. 6. IGF-I activation of the wild-type (WT) and mutant (MUT) 1.3-kb type 
IIb MyHC promoter with or without constitutively active GSK-313. A: sche- 
matic of the putative T-cell factor/lymphoid enhancer factor (Tcf/Lef) binding 
site at -1,206 to -1,201 bp in the WT 1.3-kb type IIb MyHC construct. The 
conserved Tcf/Lef binding site is underlined, and site-directed mutations are 
denoted above the original sequence. Luc, luciferase. B: C2C12 myocytes were 
transfected with the 1.3-kb WT type IIb MyHC promoter or the mutated 1.3-kb 
type IIb MyHC promoter and harvested after 3 days of differentiation in DM 
(control) or DM with 250 ng/ml IGF-I (IGF-I). Mutation of the conserved 
Tcf/Lef binding site attenuates IGF-I-induced 1.3-kb type IIb MyHC promoter 
activity. Values are expressed as a percentage of control WT 1.3-kb type IIb 
MyHC promoter activity and are reported as the average ± SE of n = 4 
wells/group. *P < 0.05 from control WT 1.3-kb promoter, $P < 0.05 from 
IGF-I WT 1.3-kb promoter. C: C2C12 myocytes were cotransfected with the 
WT 1.3-kb type IIb MyHC promoter and the pGL3 basic empty vector (EV), 
the WT 1.3-kb type IIb MyHC promoter and constitutively active glycogen 
synthase kinase-313 (caGSK-313), or the MUT 1.3-kb type IIb MyHC promoter 
and caGSK-313, then harvested after 3 days of differentiation in DM (control) 
or DM with 250 ng/ml IGF-I (IGF-I). caGSK-313 attenuates IGF-I-induced 
1.3-kb type IIb MyHC promoter activity. Values are expressed as a percentage 
of control EV WT 1.3-kb type IIb MyHC promoter activity and are reported as 
the average ± SE of n = 4 wells/group. *P < 0.05 from control WT 1.3-kb 
promoter; $P < 0.05 from IGF-I WT 1.3-kb promoter. D: nucleotide sequence 
comparison of Tcf/Lef binding sites in mouse, rat, human, and chimp type IIb 
MyHC promoters. The published mRNA sequence for type IIb MyHC for each 
respective species was input into the University of California, Santa Cruz 
Genome Bioinformatics database, and 3000 bases 5' to the transcription start 
site were retrieved and analyzed for Tcf/Lef binding site and flanking region 
homology. The following genome assemblies were used for retrieval of 
genomic DNA sequences: mouse - July 2007 (mm9); rat - November 2004 
(rn4); human - March 2006 (hg18); and chimp - March 2006 (panTro2). The 
core Tcf/Lef binding site (boxed) is conserved across these species, and the 
flanking region sequence homology is indicated by gray shading. 
effects on TEAD-protein binding specificity, affinity, and 
function (16, 31). 
Nonetheless, these data demonstrate for the first time that 
transcriptional activation of the mouse type IIb MyHC 
promoter in response to IGF-I occurs, in part, through 
components of a Tcf/Lef signaling network. Recently, 
Schakman et al. (23) reported that Akt, GSK-313, and 13-
catenin signaling plays a critical role in the anti-atrophic 
action of IGF-I in skeletal muscle atrophy caused by 
glucocorticoids. Concurrently, we were investigating whether 
the Tcf/Lef binding site and 13-cate- nin play a role in IGF-I-
induced type IIb MyHC transcriptional activity. We 
hypothesized that if IGF-I signaling occurs via the Tcf/Lef 
binding site on the type IIb MyHC promoter, IGF-I 
treatment would increase nuclear 13-catenin protein and thus 
provide further insight into the mechanism by which IGF-I 
promoted transcriptional activity of type IIb MyHC. Here, for 
the first time, we show that IGF-I increases nuclear 13 -catenin 
protein 2.8-fold in differentiating C2C12 myocytes, compared 
with differentiating C2C12 myocytes without IGF-I treatment 
(Fig. 7A). Recently, Sun and Jin (27) demonstrated that insulin 
increases nuclear 13-catenin content and induces the nuclear 
translocation and binding of 13-catenin to two Tcf-binding sites 
in the human c-Myc gene promoter in intestinal cell lines. 
Therefore, the possibility exists that increased nuclear 13-
catenin protein could interact with Tcf/Lef binding sites on the 
type IIb MyHC promoter to increase promoter activity of 
type IIb MyHC in skeletal muscle cells. 
Knockdown of [3-catenin blunts IGF-I-induced type IIb 
MyHC promoter activity and type IIb MyHC mRNA. Initially, 
we inhibited GSK-313 using LiCl, which is known to result in 
stabilization and nuclear translocation of 13-catenin (21), and 
chronically activated GSK-313 by genetic mutation in C2C12
Fig. 7. Role of 13-catenin in IGF-I-induced type IIb MyHC transcriptional 
activity. A: enriched nuclear extracts from differentiating  C2C12  myocytes 
were analyzed after 3 days of differentiation in DM (control) or DM with 250 
ng/ml of IGF-I (IGF-I). Enriched nuclear extract protein was prepared, and 
equal amounts (10 µg each) were separated by SDS-PAGE; nuclear 13-catenin 
protein levels were determined by Western blot analysis. IGF-I increased 
nuclear 13-catenin 2.8-fold, compared with control. Representative immuno- 
blots are depicted above data. Band intensity was quantified and is expressed 
in arbitrary units (AU) and reported as average ± SE, n = 4 per group. *P < 
1.5 from control. B: optimization of 13-catenin small interfering RNA 
(siRNA) transfection in differentiating C2C12 myocytes. 13-Catenin mRNA and 
GAPDH mRNA were analyzed at 2 and 3 days after initiation of differentiation 
in C2C12 myocytes transfected with increasing concentrations of 13-catenin 
siRNA (s63419; no. 3) or 25 nM nontargeting siRNA (NT siRNA; negative 
control). Inset: C2C12 myocytes were transfected with 25 nM NT siRNA, 5 nM 
GAPDH siRNA (positive control), or 3 nM 13-catenin siRNA, and 13-catenin 
and GAPDH mRNA were analyzed 2 days after initiation of differentiation. 
C: C2C12 myocytes were cotransfected with either 3 nM 13-catenin siRNA or 
25 nM NT siRNA and either the WT 1.3-kb type IIb MyHC promoter or the 
mutated 1.3-kb type IIb MyHC promoter and harvested after 3 days of 
differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I) for the 
analysis of type IIb MyHC promoter activity. Knockdown of 13-catenin with 
siRNA attenuates IGF-I-induced increases in 1.3-kb WT type IIb MyHC 
promoter activity. Values are expressed as a percentage of control NT siRNA 
WT and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 
from control NT siRNA, $P < 0.05 from IGF-I NT siRNA. D: C2C12
myocytes were transfected with either 3 nM 13-catenin siRNA or 25 nM NT 
siRNA and harvested after 3 days of differentiation in DM (control) or DM 
with 250 ng/ml IGF-I (IGF-I) for the analysis of type IIb MyHC mRNA. 
Knockdown of 13-catenin with siRNA attenuates IGF-I-induced increases in 
type IIb MyHC mRNA. Values are relative to control NT siRNA and are 
reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control 
NT siRNA, $P < 0.05 from IGF-I NT siRNA. 
 
 
myocytes, resulting in opposing effects on IGF-I-induced tran- 
scriptional activity of type IIb MyHC. In addition, we showed 
that mutation of the Tcf/Lef binding site attenuated 1.3-kb type 
IIb MyHC promoter activity. These experiments demonstrate 
that GSK-313 and the Tcf/Lef binding site at -1,206 to -1,201 
bp in the type IIb MyHC promoter play important roles in 
IGF-I-induced increases in type IIb MyHC transcriptional 
activity. However, the link that connects these two separate 
findings has yet to be described. Therefore, we sought to 
determine whether 13-catenin is involved in IGF-I-induced 
increases in type IIb MyHC transcriptional activity. 
On that note, we pursued attenuation of 13-catenin expression 
using siRNA technology. Optimization experiments on 13-cate- 
nin siRNA revealed �80% knockdown of 13-catenin mRNA 
with transfection of 3–30 nM 13-catenin siRNA (Fig. 7B). 
Furthermore, transfection of positive control GAPDH siRNA 
attenuated GAPDH mRNA levels by 50% but did not affect 
13-catenin mRNA and vice versa (Fig. 7B, inset). Moreover, 
when 13-catenin expression was knocked down using siRNA, 
IGF-I-induced 1.3-kb type IIb MyHC promoter activity was 
attenuated �50% (Fig. 7C). Moreover, no further attenuation 
of IGF-I-induced 1.3-kb type IIb MyHC promoter activity 
occurred with either mutation of the Tcf/Lef binding site on the 
type IIb MyHC promoter, or with a combination of 13-catenin 
siRNA and mutation of the Tcf/Lef binding site. Furthermore, 
knockdown of 13-catenin using siRNA showed similar attenu- 
ation of IGF-I-induced increases in type IIb MyHC mRNA 
(Fig. 7D). These results confirm the involvement of 13-catenin 
in IGF-I signaling to the Tcf/Lef binding site at -1,206 to 
-1,201 bp in the mouse type IIb MyHC promoter in 
differentiating C2C12  myocytes. 
In summary, our data are the first to demonstrate that IGF-I 
increases 1) type IIb MyHC mRNA levels, 2) transcriptional 
activity of the mouse type IIb MyHC promoter, and 3) nuclear 
levels of 13-catenin protein in differentiating C2C12 myocytes. 
We also utilized the conserved Tcf/Lef binding site at -1,206 
to -1,201 bp in the type IIb MyHC promoter as a tool to 
explore potential signaling mechanism(s) involved in IGF-I- 
induced type IIb MyHC transcriptional activation. Our data 
suggest that transcriptional activation of type IIb MyHC in 
response to IGF-I occurs, in part, through GSK-313 
inactivation, nuclear translocation of 13-catenin protein, 
and an intact Tcf/Lef binding site on the mouse type IIb 
MyHC promoter. These data provide valuable insight into 
how IGF-I modulates the complex regulatory mechanisms of 
type IIb MyHC gene expression and present a novel 
mechanism by which IGF-I may regulate transcriptional 
activity of other genes involved in muscle hypertrophy. 
Furthermore, these findings could prove valuable as a guide 
in searching for additional IGF-I-induced Tcf/Lef-dependent 
genes in skeletal muscle, other than type IIb myosin heavy 
chain. 
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